Streetwise Reports (11/20/2019)

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. read more >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data

Streetwise Reports (11/19/2019)

Shares of Myovant Sciences opened 120% higher after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. read more >

Medical Small Cap Moving Forward with Cutting-Edge Technological Innovations

Streetwise Reports (11/18/2019)

Premier Health is methodically building an innovative telemedicine platform in Canada, is purchasing a venerable telemedicine firm, and sees 2020 as the year of execution. read more >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data

Streetwise Reports (11/18/2019)

Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. read more >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Streetwise Reports (11/15/2019)

Plus Therapeutics shares traded higher after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. read more >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia

Streetwise Reports (11/15/2019)

With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. read more >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher

Streetwise Reports (11/14/2019)

Shares of Exicure Inc. opened 30% higher after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. read more >

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes

Contributed Opinion

Knox Henderson for Streetwise Reports (11/13/2019)

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes

A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. read more >

Seachange in Mexico on Cannabis Could Benefit This Small Cap

Contributed Opinion

Clive Maund for Streetwise Reports (11/13/2019)

Seachange in Mexico on Cannabis Could Benefit This Small Cap

Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. read more >

Electromed Earnings Spark a 25% Increase in Its Share Price

Streetwise Reports (11/13/2019)

Shares of SmartVest maker Electromed traded 25% higher after the firm reported Q1/20 earnings. The firm's shares set a 52-week high price after reporting a 14.1% increase in year-over-year quarterly revenue and a six-fold increase in net income per share. read more >

Expert Investing Ideas

"DRRX's psoriasis trial is on target for topline data by year-end 2019."